42 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
, is the head of the Limoges Clinical Investigation Center (Limoges, France). Dr. François took a primary role in the design of the study, medical
6-K
EX-10.1
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Report of Foreign Private Issuer
4:02pm
) or (iii), a “Material Adverse Effect”) and no “Proceeding” (which for purposes of this Agreement shall mean any action, claim, suit, investigation … or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or, to the Company’s knowledge
F-3
ghb090yd
29 Apr 22
Shelf registration (foreign)
8:14am
S-8
EX-5.1
16gvvb ifbgfl809hv5
4 Jun 21
Registration of securities for employees
4:16pm
S-8
cvdejv r0a85nmt97xp
4 Jun 21
Registration of securities for employees
4:16pm
6-K
EX-99.1
ovppc4l83vtzgbyj8k
22 Mar 21
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
dx3ybrotkv37vv
1 Mar 21
Report of Foreign Private Issuer
7:58am
6-K
EX-10.1
4u0baa59rzqic3fx3eq
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
6-K
EX-1.1
kd59q9ukib1y8kt4z
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
F-3MEF
EX-5.1
9e5o928
9 Feb 21
Registration statement to add securities to prior F-3 registration
9:40pm
6-K
EX-10.1
wjtn4wf479jdbeze
22 Oct 20
Report of Foreign Private Issuer
8:47am
6-K
EX-99.1
ywnvlutx9 n7v
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-1.1
noyhmuc6 6n
5 Mar 20
Report of Foreign Private Issuer
8:16am